PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer

Molecule-targeted therapy has achieved great progress in cancer therapy. Effective drug combinations are one way to enhance the therapeutic efficacy and combat resistance. Here, we determined the effect of the PI3K/mTOR dual inhibitor BEZ235 and the histone deacetylase inhibitor Trichostatin A (TSA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Liyan, Jin, Tiefeng, Zhu, Kun, Piao, Yingshi, Quan, Taihao, Quan, Chunji, Lin, Zhenhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355316/
https://www.ncbi.nlm.nih.gov/pubmed/28060760
http://dx.doi.org/10.18632/oncotarget.14442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355316/
https://www.ncbi.nlm.nih.gov/pubmed/28060760
http://dx.doi.org/10.18632/oncotarget.14442

Ejemplares similares